MicroRNA profiling of CD3+CD56+ cytokine-induced killer cells
Studies have proven that IL-2 and IL-15 showed contrasting roles during CIK cells preparation. By employing microarray, we analyzed miRNA expression profiles of PBMC, CIK IL-2 and CIK IL-15 . Advanced bioinformatic analyses were performed to explore the key miRNAs which may regulate cell proliferati...
Gespeichert in:
Veröffentlicht in: | Scientific reports 2015-03, Vol.5 (1), p.9571-9571, Article 9571 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Studies have proven that IL-2 and IL-15 showed contrasting roles during CIK cells preparation. By employing microarray, we analyzed miRNA expression profiles of PBMC, CIK
IL-2
and CIK
IL-15
. Advanced bioinformatic analyses were performed to explore the key miRNAs which may regulate cell proliferation and anti-tumor activity of CIK. We identified 261 differentially expressed miRNAs (DEMs) between PBMC and CIK
IL-2
and 249 DEMs between PBMC and CIK
IL-15
. MiR-143-3p/miR-145-5p was miRNA cluster which may positively regulate cell proliferation. In contrast, miR-340-5p/miR-340-3p cluster may negatively regulate cell proliferation via induction apoptosis, which may cause decreased cell proliferation capacity of CIK
IL-2.
MiRNA-target interaction analysis indicated that 10 co-downregulated miRNAs may synergistically turn on the expression of a pool of tumor cytotoxic genes in CIK cells. The DEMs between CIK
IL-2
and CIK
IL-15
may contribute to enhanced tumor cytotoxic capacity of CIK
IL-2
. Importantly, we found that repressed miR-193a-5p may regulate the expressions of inhibitory receptor KLRD1. The results of the validation assay have shown that KLRD1 were upregulated in CIK cells. Our findings have provided new insights into mechanisms of CIK cells production and tumor cytotoxic function and shed light on their safety for clinical trial. |
---|---|
ISSN: | 2045-2322 2045-2322 |
DOI: | 10.1038/srep09571 |